D r a f t

Calpain inhibitor attenuates atherosclerosis and inflammation in atherosclerotic rats through eNOS/NO/NF-κB pathway
Abstract:
We previously reported that calpain, the Ca 2+ -sensitive cysteine protease, gets involved in the atherogenesis. This study was to investigate the effects of calpain inhibitor (CAI, 5 mg/kg/d) with or without N G -nitro-L -arginine-methyl ester ( L -NAME) (100 mg/kg/d), the inhibitor of nitric oxide synthase (NOS), on atherosclerosis and inflammation in rat model induced by high cholesterol diet (HCD). The results demonstrated HCD increased protein expression of calpain-1 but not calpain-2 in aortic tissue. In addition, CAI reduced the thickness of atherosclerotic intima compared to HCD group, which was weakened by the L -NAME combination. CAI with or without L -NAME decreased the activity of calpain in the aorta. Besides, CAI decreased the expressions of vascular cell adhesion molecule-1 (VCAM-1), intracellular cell adhesion molesul-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1) in the aorta at the levels of both mRNA and protein.
Furthermore, CAI increased the activity and the protein expression of endothelial NOS (eNOS) accompanied by increased content of NO and down-regulated the protein
Introduction
Atherosclerosis has been reported to be the main cause of coronary artery disease (CAD) and stroke (Peters et al. 2012 ). Vascular endothelial dysfunction-mediated inflammatory response gets involved in the initiation and development of atherosclerosis.
Endothelial dysfunction contributes to atherosclerosis largely due to the decrease in bioavailability of nitric oxide (NO) which is originated from endothelial NO synthase (eNOS) (Sharma et al. 2015) . Compared with apolipoprotein E knockout (ApoE KO) mice, ApoE/eNOS double KO mice showed the increase in atherosclerotic lesion, which suggested that eNOS protects the ApoE KO mice against the development of D r a f t atherosclerosis (Kus et al. 2014) . In addition, the combination of a NO-donating property enhances the anti-atherogenic activity of atorvastatin (Momi et al. 2012) . Endothelial dysfunction-mediated inflammation contributes to the atherogenesis largely depending on the induction of expression of inflammatory molecules including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) (Shah et al. 2015) . Release impairment of NO from endothelial cells leads to the up-regulation of ICAM-1, VCAM-1 and that NO synthesis inhibition increases the gene expression of MCP-1 in endothelial cells (Kang et al. 2005; Khan et al. 1996; Sohn et al. 2005a ). Administration of NO donors to the animal deficient in NO maintains the endothelial function and inhibits pathological interactions between leukocytes in the circulation and the vascular endothelium (De Caterina et al. 1995; Sohn et al. 2005b ). In addition, the expressions of ICAM-1, VCAM-1 and MCP-1 are associated with the activation of nuclear factor κB (NF-κB), a transcription protein (Zeiher et al. 1995) . In the physiological state, as a heterodimer of the p50 and p65
subunits, NF-κB stays in the cytoplasm. However, upon stimulation in the pathological state, p50 and p65 can go to the nucleus, where affecting the expression of genes such as ICAM-1, VCAM-1 and MCP-1 (Hall et al. 2006; Jones et al. 2003) .
Calpains, the Ca 2+ dependent cysteine proteases, strictly regulate their substrate proteins by the limited proteolysis (Subramanian et al. 2012 ). Calpain family is comprised of 15 homologues of catalytic subunits and 2 homologues of regulatory subunits. Among the superfamily, Calpain-1 and calpain-2 are categorized as "conventional calpain" (Daugherty et al. 2000) . By using pharmacological inhibitors or mice deficient in calpain-1 or calpain-2 or mice over-expressing calpastatin, the endogenous inhibitor, many studies demonstrated that inactivation of calpain inhibited atherosclerosis, suggesting the involvement of calpains in the development of atherosclerosis (Clinkinbeard et al. 2013; Hua and Nair 2015; Miyazaki et al. 2013; Ruetten and Thiemermann 1997; Takeshita et al. 2013) . We previously reported that calpain-1 gets involved in the atherogenesis by up-regulating the scavenger receptor CD36 expression (Yang et al. 2016) . In addition to conventional calpain, one of unconventional calpain isozyme, calpain-6, appears to be induced in macrophages during atherogenesis, thereby facilitating form cell formation (Miyazaki et al. 2016) . Calpains D r a f t have also been implicated to play a critical deleterious role in endothelial dysfunction (Stalker et al. 2003) . Activated calpain by Ca 2+ damages the cells by the selective degradation of the proteins such as eNOS and IκB (Averna et al. 2008; Dong et al. 2009 ).
Calpains also mediates the inflammatory processes via the NF-κB activation (Li et al. 2014 ). Taken together, these studies indicated that calpains get involved in the atherosclerosis largely through endothelial dysfunction and inflammatory response.
Nevertheless, the molecular mechanisms underlying the involvement remain to be investigated. This study was to evaluate the significance of NO in the inhibition of atherosclerosis by calpain inhibitor CAI in rat model with early atherosclerosis induced by high dose of vitamin D2 and diet with high content of cholesterol. The results demonstrated that CAI inhibited the atherosclerosis through eNOS/NO/NF-κB pathway.
Materials and methods
Chemicals
Calpain inhibitor I (N-acetyl-leu-leu-norleucinal, CAI) was the product of Santa Cruz Biotechnology (sc-29119, MW: 383.5). N G -nitro-L -arginine-methyl ester ( L -NAME) was purchased from Beyotime Institute of Biotechnology, Shanghai, China. rats (Animal Center, Jinzhou Medical University, China) were randomly and equally divided into Control, HCD, CAI and CAI+ L -NAME groups. The atherosclerotic rat model was established as described previously (Tang et al. 2006a) . Briefly, vitamin D 2 (300,000 IU/kg/day) (Sigma) was given to all rats by gavage for 4 days followed by fed with animal chow in control group (Con) and high cholesterol diet (HCD) containing 2% cholesterol in HCD, CAI and CAI+ L -NAME groups for 8 weeks. Rats in CAI and CAI+ D r a f t L -NAME groups were intraperitoneally injected CAI (0.5mg/kg/day) combined with or without L -NAME (100 mg/kg/d). At the end of the experiment, the blood was collected from eyes of rats under light anesthesia by ether from which serum was separated for biochemical analysis. The rats were then sacrificed by peritoneal injection of over dose of pentobarbital sodium (30 mg/kg) and the aortic issue was separated.
Atherosclerosis model of rats
Morphological changes in aortic arch
Six-micrometer-thick section of aortic arch fixed in 10% formalin was stained with hematoxylin and eosin as previously reported method (Tang et al. 2007 ) and the ratio of thickness between intima (I) and intima plus media (I+M) was calculated.
Contents of cholesterol in aorta and lipid profiles in serum
Cholesterol content in lysate of aorta and the serum levels of total cholesterol (TC), triacylglycerol (TG), low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol were determined using kit from Beijing Zhongsheng
Bioengineering Company (China) as previously reported method (Tang et al. 2007; Tang et al. 2006a ).
Activity of calpain in aorta
Calpain activity in lysate of aorta was measured using a fluorescence substrate N-succinyl-LLVY-AMC (Amyjet Scientific Inc, China) as previously reported method .
Content of NO and eNOS activity in aorta
NO content and eNOS activity in lysate of aorta was determined using kit from Nanjing Jiancheng Bioengineering Company (China) as previously reported method (Tang et al. 2006b ).
Immunohistochemical analysis of eNOS in vascular endothelia
Sections of aortic arch were used to determine the protein expression of eNOS as previously reported method (Tang et al. 2007 ). The first and second antibody was rabbit D r a f t anti-rat eNOS and sheep anti-rabbit IgG-peroxidase antibodies provided by Abcam
Company (Cambridge, MA, USA) respectively.
Contents of VCAM-1, ICAM-1 and MCP-1 in aorta
Contents of VCAM-1, ICAM-1 and MCP-1 in lysate of aorta was measured using ELISA kits from R&D Systems (Minneapolis, MN, USA) as previously reported method ). The color absorbance at 450 nm was measured using a Bio-Rad microplate reader.
mRNA expression of ICAM-1, VCAM-1 and MCP-1 in aorta
The mRNA expression of ICAM-1, VCAM-1 and MCP-1 in aorta was analyzed using the BioRad iQ5 Real Time PCR system (BioRad Company) as previously reported method . Primers used for qPCR are provided in Table 1 . 
Protein expressions of calpain-1, calpain-2, CD68, eNOS and NF-κB in aorta
The protein expression of calpain-1, calpain-2, CD68, eNOS and p65 in aorta was examined using Western blot as previously reported method (Luan et al. 2015; Tang et al. 2016 ). Nuclear proteins in aortic tissue were separated using Nuclear and Cytoplasm Extraction Kit (Active Motif provided by Dakewe Biotech Limited, China) as previously reported method . Antibodies against eNOS (1.1000), p65 (1:1500), lamin B (1:1000) and GAPDH (1:500) were from Abcam (Cambridge, MA, USA).
Antibodies against calpain-1 (1:1000), calpain-2 (1:1000) and CD68 (1:2000) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Statistical analysis
Data are shown as the mean ±SEM and analyzed by one-way analysis of variance (ANOVA) and the t-test using SPSS 17.0 software. P<0.05 showed the statistically D r a f t significant difference.
Results
CAI reduces the atherosclerosis and CD68 protein expression independent of the serum lipid profiles
As shown in Figure 1 , rats in HCD group demonstrated the significant increases in the ratio of I to (I+M) ( Figure 1A and 1B), the cholesterol content ( Figure 1C ) and CD68
protein expression ( Figure 1D ) in the aorta, all representing the formation of atherosclerosis. However, these increases were attenuated by CAI, the specific calpain inhibitor, suggesting that activation of calpain implies in the pathogenesis of atherosclerosis. In addition, combination of L -NAME, the specific NOS inhibitor, with CAI partly abolished the inhibitory effects of CAI on atherosclerosis. The results indicated that CAI reduces the atherosclerosis at least partly through regulation of NOS/NO pathway. Furthermore, both CAI and L -NAME did not affect the lipid profiles in serum changed by HCD ( Figure 1E ), suggesting that the actions of CAI and L -NAME on atherosclerosis are independent of serum lipid profiles.
CAI inactivates calpain without affecting the protein expressions of calpain-1 and calpain-2
Calpain activity ( Figure 2A ) and calpain-1 protein expression ( Figure 2B ) in aortic tissue of rats in HCD group increased compared with that of control rats. CAI reduced the calpain activity without affecting the protein expression of calpain-1. Calpain activity was comparable between CAI and CAI+ L -NAME groups. CAI in combination with or without L -NAME had no effect on calpain-1 protein expression compared with HCD. In addition, the protein expression of calpain-2 was unchanged among all four groups.
These results suggested that inactivation of calpain rather than down-regulation of calpain-1 or calpain-2 protein expression by CAI contributes the inhibition of atherosclerosis. showed the significant decreases in the NO content ( Figure 3A ) and eNOS activity ( Figure 3B ) and protein expression ( Figure 3C and 3D) in rat aorta of HCD group compared with that in control group, suggesting that deficiency of NO production might contribute to the atherosclerosis. However, these decreases were changed inversely by CAI. Expectedly, combination of L -NAME with CAI partly reduced the effects of CAI on NO content and eNOS activity without affecting the eNOS protein expression. Taken together, the results further confirmed the hypothesis that enhancement of eNOS/NO pathway gets involved in the inhibition of CAI on atherosclerosis.
CAI increases the
CAI inhibits the expressions of ICAM-1, VCAM-1 and MCP-1 in aorta
The results indicated that the mRNA and protein expressions of vascular inflammatory molecules ICAM-1 ( Figure. 4A and 4B), VCAM-1 ( Figure. 4C and 4D) and MCP-1 ( Figure. 4E and 4F) in HCD group significantly increased compared with that in control group. However, these increases were reduced by CAI, which might at least partly explain the mechanism underlying the inhibition of atherosclerosis by CAI. In addition, combination of L -NAME with CAI partly abolished the effects of CAI on these inflammatory molecules. Taken together, the results indicated that inhibition of inflammation by CAI might be consequence of the enhancement of eNOS/NO pathway.
CAI reduces the NF-κB translocation into nucleus of aorta
NF-κB activation and nuclear translocation regulates the inflammation. Therefore, we examined the protein expression of p65, the subunit of NF-κB in both cytoplasm and nucleus of aorta to clarify the mechanisms underlying the regulation of inflammation by CAI. The results showed that p65 protein expression significantly decreased in cytoplasm 
Discussion
We reported in this study that CAI, the specific inhibitor of calpain, attenuated the atherosclerosis, increased the activity and the protein expression of eNOS, elevated the content of NO, down-regulated the expression of ICAM-1, VCAM-1 and MCP-1 and inhibited the nuclear translocation of NF-κB in aorta. However, all the beneficial effects of CAI were partly abolished by L -NAME, the specific inhibitor of NOS, except for the protein expression of eNOS. The results suggested that CAI inhibited the atherosclerosis through eNOS/NO/NF-κB pathway.
By using pharmacological inhibitors or mice deficient in calpain-1 or calpain-2 or mice over-expressing calpastatin, the endogenous inhibitor, many studies demonstrated that inactivation of calpain inhibited the atherosclerosis, suggesting that calpains gets involved in the pathogenesis of atherosclerosis (Clinkinbeard et al. 2013; Hua and Nair 2015; Miyazaki et al. 2013; Ruetten and Thiemermann 1997; Takeshita et al. 2013 ).
Expectedly, the present results demonstrated that CAI attenuated the atherosclerotic lesion and reduced the vascular content of cholesterol in rats fed with high cholesterol diet and excessive vitamin D. However, combination of CAI with L -NAME partly abolished the inhibitory effect on atherosclerosis by CAI, suggesting that regulation of endothelial NOS/NO pathway might contribute the inhibitory effect of CAI on atherosclerotic lesions. Accumulative studies reported that the increase in production of endothelial NO protected animals against atherosclerosis (De Caterina et al. 1995; Momi et al. 2012; Zeiher et al. 1995) . Regarding the roles of calpain-1 and calpain-2 in the formation of atherosclerosis, both calpain-1 and calpain-2 are reportedly expressed in macrophages in angiotensin II-infused athero-prone aorta, and are associated with their inflammatory responses (Howatt et al. 2016 ). In addition, calpain-2 appears to be upregulated in vascular endothelium during atherogenesis, and is contributed to endothelial barrier dysfunction (Miyazaki et al. 2011) . We examined the protein expression of calpain-1 and calpain-2 in the aortic tissue and found that protein D r a f t expression of calpain-1 rather than calpain-2 in atherosclerotic rat model increased compared with that of control rats, suggesting that calpain-1 but not calpain-2 plays important role in the formation of atherosclerosis of rat model. The present result was not consistent with these reports and the inconsistency might be attributed to the different animal models.
To further clarify the involvement of eNOS/NO pathway in the mechanism underlying the inhibition of CAI on atherosclerosis, we examined the NO content, eNOS activity and 
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These results indicated that inhibition of inflammation by CAI was mediated by the improvement of eNOS/NO pathway. Consistently, studies using atherosclerotic model mice lacking of VCAM-1 or MCP gene or the mice over-expressing MCP-1 gene, have showed the importance of these gene in atherogenesis (Cybulsky et al. 2001; Nelken et al. 1991) . Furthermore, NO synthesis inhibition by high dosage of L-NAME to rats induces vascular inflammation and atherosclerosis (Kataoka et al. 2004 ). These investigations indicate that inflammation responses in atherogenesis are closely linked with the impaired NO synthesis, and therefore improvement of NO production might be one of the approaches for anti-inflammation, and anti-atherosclerosis. Regarding the mechanisms by which calpain regulates the eNOS/NO function, subsequently inducing the inflammation, there is study revealing that glucose induces loss of NO via a calpain-dependent decrease in the association of heat shock protein 90 (hsp90) with eNOS (Stalker et al. 2003) . In addition, inhibition of calpain activity decreased endothelial cell surface expression of the pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 during hyperglycemia (Stalker et al. 2003 ). These data demonstrate that calpains contribute to important inflammatory events during hyperglycemia and that pharmacological inhibition of calpain activity attenuates leukocyte endothelium interactions and preserves eNOS function.
The expressions of inflammatory molecules can be up-regulated by NF-κB activation.
In the physiological state, as a heterodimer of the p50 and p65 subunits, NF-κB stays in the cytoplasm. However, upon stimulation in the pathological state, p50 and p65 can go to the nucleus, where affecting the expression of genes such as ICAM-1, VCAM-1 and MCP-1 (Chen et al. 1995) . To examine the mechanism underlying the eNOS/NO-mediated inhibition of inflammation by CAI, we observed the effect of CAI on p65 translocation into nucleus. The study demonstrated that CAI attenuated the p65 nuclear translocation, which was partly abolished by combination of L -NAME. Part of this result was supported by the finding that knockdown of endogenous P65 in HUVECs through siRNA decreased the expressions of ICAM-1 and VCAM-1 at the mRNA and protein levels (Wu et al. 2014) . Taken together, these results indicated that CAI inhibited the endothelial inflammation at least in part through eNOS/NO mediated attenuation of p65 translocation into nucleus, subsequently reducing the atherosclerosis.
In summary, the results suggested that CAI attenuated the inflammation and D r a f t atherosclerosis in rats through eNOS/NO/NF-κB pathway.
This study has several limitations. Firstly, HCD+ L -NAME group should be assigned to investigate the effect of L -NAME alone on the atherosclerosis, which might exclude the direct effect of L -NAME on the atherosclerosis. Secondly, the use of non-selective inhibitor of NOS, L -NAME can not exclude the facts that other isoforms of NOS, as well as arginase might be also involved in pathogenesis, which requires the use of selective inhibitor of NOS in the future study. Finally, the study lacks the mechanisms by which calpain regulates the eNOS/NO pathway, which requires further investigation in the future study, e.g. by checking the dissociation of HSP90 from eNOS.
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